Though the most common current treatment for colorectal cancer is surgical, there are currently four FDA-approved immunotherapies―bevacizumab, cetuximab, ramucirumab, and panitumumab―all targeted antibodies. Furthermore, colorectal cancer is of the top cancer types for which immunotherapies are being evaluated.